New Insights into Neuromyelitis Optica by Kim, Woojun et al.
Copyright © 2011 Korean Neurological Association  115
Print ISSN 1738-6586 / On-line ISSN 2005-5013
http://dx.doi.org/10.3988/jcn.2011.7.3.115
REVIEW
J Clin Neurol 2011;7:115-127
Introduction
Neuromyelitis optica (NMO, also known as Devic’s disease) 
is an idiopathic inflammatory syndrome of the central nervous 
system (CNS) that is characterized by severe attacks of optic 
neuritis (ON) and myelitis.
1 NMO was first described in 1870 
by T. Clifford Allbutt, who reported an association between 
myelitis and unilateral optic nerve disorder.
2 In 1894, Eugène 
Devic coined the term “neuromyelite optique aigue” (acute 
optic neuromyelitis) to describe 16 patients who had lost vi-
sion unilaterally or bilaterally and within weeks developed 
severe spastic paraparesis or tetraparesis, loss of sensation, and 
often loss of sphincter control. These symptoms were recogniz-
ed as resulting from inflammation affecting both the optic ner-
ve and the spinal cord.
3 For the next 100 years, NMO was con-
sidered to be a monophasic, devastating disorder that affected 
the optic nerves and the spinal cord, but spared the remainder 
of the CNS.
There has long been controversy as to whether NMO is a 
variant of multiple sclerosis (MS) or a distinct disease. A land-
mark advance in this regard was the identification of a disease-
specific autoantibody, NMO-IgG, in the serum of patients with 
NMO.
4 NMO-IgG binds selectively to aquaporin (AQP)-4 
(AQP4), a water channel that is densely expressed in astrocy-
tic foot processes at the blood-brain barrier (BBB).
5 This find-
ing has prompted revisions of the diagnostic criteria for NMO
6 
and facilitated an appreciation for the wide spectrum of this 
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disorder, which includes a proportion of patients with recur-
rent, isolated, longitudinally extensive myelitis (LEM) or ON, 
and LEM or ON associated with systemic autoimmune disease 
or with brain lesions typical of NMO. Thus, the concept of 
“NMO spectrum disorders” (NMOSDs) was introduced.
1 In re-
cent years, the clinical spectrum, immunological/pathological 
profiles, and management issues regarding NMO or NMOSDs 
have been better characterized. This review focuses on the 
new concepts of NMO based on its pathophysiology and cli-
nical characteristics. Potential management strategies for NMO, 
in light of its pathomechanism, are also discussed.
Epidemiology and Genetic 
Predisposition
While there have been few relevant population-based stud-
ies, the prevalence of NMO has been estimated by its frequ-
ency relative to MS, and has been estimated at 1 per 100,000 
population.
7-9 In a retrospective, cross-sectional study perform-
ed in Italy, the prevalence of NMOSDs was 1.5%, with a ratio 
of 42 MS cases to 7 NMOSD cases.
10 However, the proportion 
of cases with a non-Caucasian background is significantly 
greater. NMO is believed to be linked to 30-40% of MS cases 
in Japanese,
11 16.8% in African-Americans,
12 and 15% in Afri-
can-Brazilians.
13 NMO predominantly affects females, with a 
female-to-male ratio of 9:1. The median age at onset of NMO 
is the late 30s;14,15 however, there have been several reports of 
NMO cases in childhood
16-18 and in the elderly.
19 NMO is not 
generally considered to have a familial tendency.
14 However, 
genetic susceptibility is possible, since the reported incidence 
of familial cases of NMO appears to be higher than expected 
based on its frequency in the general population.
20-25
NMO was reported to be associated with the human leu-
kocyte antigen DPB1*0501 allele in the Japanese,
26,27 but fur-
ther analysis of patients with pure opticospinal MS (OSMS) 
who had consistently normal brain magnetic resonance im-
aging (MRI) scans suggested that OSMS is not necessarily 
associated with DPB1*0501.
28 DPB1*0501 was recently re-
ported to be associated with NMO in the Han population of 
southern China.
29
Immunopathology
Pathology of NMO lesions
The pathology of NMO lesions was initially described from 
autopsied cases by Lucchinetti et al.
30 Extensive demyelin-
ation was found to be present across multiple spinal cord 
levels and was associated with cavitation, necrosis, and acute 
axonal pathology (spheroids), in both the gray and white mat-
ter. There was a marked loss of oligodendrocytes within the 
lesions. The inflammatory infiltrates in active lesions were ch-
aracterized by extensive macrophage infiltration associated 
with large numbers of perivascular granulocytes and eosino-
phils, and a few T cells. There was pronounced perivascular 
deposition of immunoglobulins (mainly IgM) and comple-
ment C9neo antigen in active lesions associated with promi-
nent vascular fibrosis, and hyalinization in both the active and 
inactive lesions. These findings support a role for humoral im-
munity in the pathogenesis of NMO.
Discovery of NMO-IgG
In 2004, an antibody that reacted specifically with mouse br-
ain was identified in the serum of NMO patients.
4 This anti-
body, named NMO-IgG, was present in the CNS microvessels, 
pia, subpia, and Virchow-Robin spaces, and was partly colo-
calized with laminin. This tissue-based indirect immunofluo-
rescence assay (IIFA) was sensitive (73%) and highly specific 
(91%) to NMO. NMO-IgG was also detected in about half of 
patients with syndromes that placed them at high risk for 
NMO, such as idiopathic isolated recurrent ON or LEM. Dur-
ing the following year, the same researchers proved that AQP4 
is the target antigen of NMO-IgG by showing that NMO-IgG 
binds selectively to AQP4-transfected human embryonic kid-
ney (HEK)-293 cells.
5
AQPs and AQP4
AQPs are water-channel proteins that assemble as homotet-
ramers in cell membranes and play a major role in fluid ho-
meostasis. AQP4 is one of 13 members of the AQP family 
(AQP0-AQP12) present in mammals and is the predominant 
AQP in the brain.
31 AQP4 is found throughout the brain, but 
is particularly abundant in the optic nerves and spinal cord.
32 
Other organs that contain AQP4 include the lung, skeletal 
muscle, stomach, inner ear, and kidney.
33 In rats, AQP4 is pre-
sent on astrocytic foot processes along the endothelial tight 
junctions at the BBB, on the abluminal side of cerebral mi-
crovessels, within the cerebellar Purkinje cell layer, and in 
the hypothalamus.
34
AQP4 exists in two isoforms, M1 (34 kDa) and M23 (32 
kDa), both of which function as water channels and form st-
able tetramers. The relative abundances of the AQP4 isoforms 
vary with the tissue type, with the rat brain containing appro-
ximately three AQP4-M23 proteins per one AQP4-M1 pro-
tein. Freeze-fracture electron microscopy of cells transfected 
with AQP4-M1 versus AQP4-M23 has demonstrated that only 
the M23 form assembles into large orthogonal arrays of more 
than 100 particles; AQP4-M1 tetramers were largely dispers-
ed and only occasionally formed small arrays of fewer than 12 
particles.
35 There remains a controversy regarding which iso-
form is the major target of the AQP4 antibody (AQP4-Ab). A  Kim W et al.
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study employing Western blotting found AQP-M1 to be the spe-
cific target of the AQP4-Ab.
36 However, in another study using 
cell-based IIFA, the sensitivity with AQP4-M1 transfected 
cells was lower for NMO (70%) and high-risk NMO (39%), 
suggesting that NMO-IgG targets mainly AQP4-M23.
37
Role of AQP4-Ab in the pathogenesis of NMO
There is a series of clinical studies showing that AQP4-Ab par-
ticipates in the pathogenesis of NMO and that AQP4-Ab may 
be predictive of relapse and/or later conversion to definite 
NMO.
38,39 Among 23 patients with LEM (14 seronegative and 
9 seropositive) followed for 1 year, none of the seronegative 
patients experienced a relapse or developed ON, whereas 5 
of the seropositive patients experienced a second event: 4 (44%) 
developed recurrent myelitis and 1 (11%) developed ON.
38 Si-
milarly, among 12 seropositive ON patients for whom long-
term follow-up was possible, 6 (50%) experienced an episode 
of myelitis and fulfilled the diagnostic criteria for NMO. Fur-
thermore, the final visual score of seropositive patients was 
worse than that of seronegative patients.
39
AQP4-Ab titers also appear to be correlated with disease 
activity. In a cross-sectional study of 148 Japanese patients, 
higher antibody titers measured with a semiquantitative cell-
based assay were associated with complete blindness and ex-
tensive or large cerebral lesions on MRI.
40 The length of spi-
nal cord lesions on MRI was positively correlated with the 
antibody titer at the nadir of exacerbation. AQP4-Ab titers 
decreased after high-dose methylprednisolone, and a follow-
up showed that the antibody titers remained low during re-
lapse-free periods under immunosuppression.
40,41 In our expe-
rience, the AQP4-Ab levels measured by enzyme-linked im-
munosorbent assay (ELISA) changed with disease activity. 
Of 38 NMOSD patients who were initially seropositive, 21 
became seronegative under effective immunosuppressive th-
erapy, and 17 continued to be seropositive. During most re-
lapses, the serum AQP4-Ab levels were either higher or incre-
asing compared with previous levels. However, rising anti-
body levels did not always lead to acute exacerbation. Among 
13 patients who were initially seronegative, 2 converted to 
seropositivity following acute exacerbation.
42 In a study in-
volving eight NMO-IgG positive patients, a fluoroimmuno-
precipitation assay revealed that relapses were preceded by 
an increase in antibody titer of up to threefold, which was pa-
ralleled by a rise in other serum autoantibodies in only one 
patient. Moreover, AQP4-Ab titers correlated with CD19
+ cell 
counts during therapy with rituximab. Treatment with immu-
nosuppressants resulted in markedly reduced antibody levels 
and relapse rates.
41 Together these results suggest that NMO 
and high-risk syndrome are associated with AQP4-Ab titer, 
and that this antibody titer has significant clinical and immu-
nological implications in NMO.
Pathological data also support the existence of a relation-
ship between AQP4-Ab and NMO pathogenesis. In acute and 
chronic NMO lesions, AQP4 immunoreactivity was lost, and 
glial fibrillary acidic protein (GFAP) staining was decreased. 
Myelin basic protein (MBP)-stained myelinated fibers were 
relatively preserved, despite the loss of AQP4 and GFAP st-
aining. The areas surrounding the lesions in NMO exhibited 
enhanced expression of AQP4 and GFAP, reflecting reactive 
gliosis. These features in NMO are distinct from those of MS 
and suggest that astrocytic impairment is associated with the 
loss of AQP4.
43
In an in vitro study, AQP4-Ab bound to AQP4-expressing 
cells, activated human and rabbit complement, and caused 
plasma cell membrane lysis.
44-46 In a study using AQP4-ex-
pressing HEK-293 cells, serum IgG (predominantly IgG1) 
from patients with NMO bound to the extracellular domain of 
AQP4 and initiated two potentially competing outcomes: AQP4 
endocytosis/degradation and complement activation.
44
NMO-IgG binding to human fetal astrocytes has been found 
to alter the polarized expression of AQP4 and increase the per-
meability of the human BBB. The binding of NMO-IgG to hu-
man fetal astrocytes was demonstrated to induce degranula-
tion of natural killer cells, astrocyte killing by antibody-de-
pendent cellular cytotoxicity, and complement-dependent 
granulocyte attraction.
47 The AQP4-Ab-induced astrocytopa-
thy was shown to occur via necrosis rather than apoptosis.
46 
In contrast, neurons and myelin appear to be preserved at the 
initiation of the inflammatory process. In line with pathologi-
cal findings, Takano et al.
48 recently reported a prominent el-
evation of cerebrospinal fluid (CSF)-GFAP during the acute 
phase of NMO, but only a modest elevation of CSF-MBP. De-
myelination may occur secondarily by excitotoxicity due to 
impaired glutamate homeostasis. Hinson et al.
49 found that pa-
tient serum and active complement compromised the mem-
brane integrity of CNS-derived astrocytes. Without comple-
ment, astrocytic membranes remained intact, but AQP4 was 
endocytosed, with the concomitant loss of Na
+-dependent glu-
tamate transport by excitatory amino acid transporter
2,49 re-
sulting in the deterioration of glutamate homeostasis.
50
Animal studies of NMO
Several studies have employed animal models of NMO.
51-55 
IgG obtained from NMO patients was injected intraperitone-
ally into a rat with experimental autoimmune encephalomy-
elitis (EAE), and the passive transfer of NMO-IgG exacerbat-
ed the neurologic deficit.
51 The active lesions of the rats ex-
hibited pathological characteristics similar to those of NMO, 
including loss of astrocytes and perivascular deposition of im-
munoglobulin and complement. Interestingly, GFAP was rel-New Insights into NMO
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atively preserved in lesions completely lacking AQP4, sug-
gesting that AQP4 was the primary target in the model. In-
tracerebral injection of NMO-IgG and human complement 
also produced NMO lesions in wild-type mice.
52 Bradl et al.
53 
also demonstrated that NMO-IgG is capable of transforming 
T-cell-mediated EAE into an NMO-like pathology. However, 
NMO-IgG injected into naive rats, young rats with a leaky 
BBB, or rats after the transfer of a nonencephalitogenic T-
cell line did not induce disease or pathological alterations in 
the CNS, suggesting that other factors such as T cells are ne-
cessary to trigger active disease in NMO.
53
Role of T cells and IgM in the pathogenesis 
of NMO
A recent study has functionally characterized AQP4-specific 
T cells.
56 Using overlapping 15-residue peptides of AQP4, the 
immunogenic T-cell epitopes of AQP4 were found to be re-
stricted to murine major histocompatibility complex I anti-
body. The N-terminal region of AQP4, or more precisely, the 
intracellular epitope AQP422-36, was detected as a major im-
munogenic determinant, along with five more immunogenic 
epitopes. T cells specific for AQP422-36 and AQP4289-303 were 
present in the natural T-cell repertoire of wild-type C57BL/6 
mice. However, active immunization with these AQP4 pep-
tides did not induce signs of spinal cord disease. Rather, sen-
sitization with AQP4 peptides resulted in the production of 
interferon (IFN)-γ as well as interleukin (IL)-5 and IL-10 by 
antigen-specific T cells. Consistent with this cytokine profile, 
the antibody response upon immunization with full-length 
AQP4 included IgG1 and IgG2, which are associated with a 
mixed T-helper (Th)2/Th1 T-cell response.
56
Typically 20-30% of patients with NMO are negative for 
AQP4-IgG, but it is not known whether AQP4-IgG-negative 
patients with NMO constitute a pathogenetically distinct dis-
ease group. The role of AQP4-IgM may be important in this 
context. Compared with IgG, IgM antibodies are more po-
tent activators of the complement pathway and are detectable 
at NMO lesional sites. Using a cell-based assay with HEK-
293 cells, anti-AQP4 IgM antibody was detected in 4 of 42 
samples from patients with NMOSD, but in none of the 66 
control samples. In three patients, antibody titers were higher 
following the depletion of total IgG from the samples. One 
sample was positive only after the precipitation of total IgG. 
Nevertheless, the role of IgM in the pathogenesis of NMOS-
Ds has not yet been determined.
57
To summarize what is known about the pathogenesis of 
NMO, the complement-activating AQP4-Ab, mainly IgG1, is 
hypothesized to play a critical role in the development of NMO 
lesions. After the antibody crosses the BBB, it binds to AQP4 
molecules on astrocyte foot processes and activates comple-
ment. Activated complement mobilizes neutrophils and eo-
sinophils, which then facilitate tissue destruction. The excito-
toxicity attributable to impaired glutamate homeostasis cau-
ses subsequent secondary demyelination. However, serum 
AQP4-Ab alone may not be sufficient to induce a clinical out-
break; other factors, such as an increase in BBB permeabili-
ty, complement activation, and the action of antigen-specific 
T cells, may also be needed.
Relationship between NMOSDs  
and Other Autoimmunities
NMO has occasionally been associated with other autoim-
mune diseases, including hypothyroidism, Sjögren’s syndrome 
(SS), systemic lupus erythematosus (SLE), pernicious anemia, 
ulcerative colitis, primary sclerosing cholangitis, rheumatoid 
arthritis, mixed connective tissue disorders, and idiopathic 
thrombocytopenic purpura.
14,58 Neuronal and muscle antibo-
dies commonly coexist with NMO and its marker, NMO-IgG.
59 
Muscle acetylcholine receptor antibodies were detected in 
13% of NMO patients. Several cases with NMO and myas-
thenia gravis were also reported.
60-62 Non-organ-specific au-
toantibodies such as antinuclear antibodies or SS-A antibodies 
were often found in patients with NMO or NMOSDs. How-
ever, NMO-IgG is highly specific to NMO and does not oc-
cur in many other conditions that have been studied as con-
trol diseases with alternative causes for severe myelopathy 
(e.g., documented viral myelitis, vitamin B12 deficiency, sar-
coidosis, and tumor) or optic neuropathy (e.g., ischemic or 
compressive ON).
4,63 Therefore, NMOSDs with seropositive 
findings for NMO-IgG occurring with SS/SLE or non-organ-
specific autoantibodies are indications of coexisting NMO, 
rather than vasculopathic or other complications of SS/SLE.
58
Clinical, Imaging, and  
Laboratory Features
Clinical features
NMO patients can have a monophasic or relapsing course. Al-
though a monophasic course of acute transverse myelitis si-
multaneously associated with ON is classical, more than 90% 
of patients experience a relapsing course.
50 ON can be sepa-
rated from transverse myelitis by months or years, and episo-
des tend to relapse, with significant accumulation of disabili-
ty. Among patients who developed a relapsing course, 55% 
had experienced their first optic nerve or spinal cord relapse 
within 1 year, 78% within 3 years, and 90% within 5 years.
64
Predictors of a relapsing course are a longer interattack in-
terval between the first two clinical events, older age at onset, 
female gender, and less severe motor impairment with the  Kim W et al.
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sentinel myelitis event. A history of other autoimmune disea-
ses, higher attack frequency during the first 2 years of the dis-
ease, and better motor recovery following the index myelitis 
event are associated with mortality due to relapsing NMO.
65 
Final assessments of visual acuity, motor strength, and sen-
sory function were worse in the relapsing group than in the 
monophasic group. A simple clinical observation that should 
suggest NMO is the attack severity; individual ON and my-
elitis attacks are more severe in NMO compared with MS, 
and the recovery is less complete.
65 Prominent dysesthetic, 
radicular pain, possibly associated with Lhermitte’s symp-
tom, is common and occurs in up to 35% of acute severe my-
elitis attacks in relapsing NMO.
14 Respiratory failure caused 
by acute cervical myelitis can also be associated with NMO. 
In a study performed in the late 1990s, 33% of relapsing pa-
tients and 9% of monophasic patients experienced respirato-
ry failure. The 5-year survival rates were 90% in the mono-
phasic group and 68% in the relapsing group. All deaths in 
the relapsing group resulted from respiratory failure.
14
NMO has traditionally been regarded as a disease without 
brain involvement, and a negative brain MRI at disease onset 
has been considered a major supportive criterion for the diag-
nosis of NMO.
14 However, NMO is not confined to the spinal 
cord or optic nerves. In fact, patients who present with brain 
symptoms at their first manifestation are not rare. We found 
that 15 of 83 NMOSD patients presented with brain symp-
toms.
66 Their initial brain manifestations were classified into 
two groups according to clinical characteristics: 1) encepha-
lopathy mimicking acute disseminated encephalomyelitis or 
posterior reversible encephalopathy syndrome, and 2) char-
acteristic brainstem symptoms such as intractable hiccup and 
vomiting. Most of the brain symptoms and lesions resolved. 
Pediatric NMO, in particular, has diverse clinical presenta-
tions. Patients can present with cerebral symptoms such as 
encephalopathy, aphasia, or seizure.
67 Intractable hiccup and 
nausea are symptoms unique to relapsing NMO and are asso-
ciated with a linear medullary or medullospinal lesion in-
volving the pericanal region, the area postrema, and the nu-
cleus tractus solitarius,
68 which are sites of high AQP4 ex-
pression.
69 Since those lesions were not detected in MS cases, 
a linear medullary lesion causing intractable hiccup and nau-
sea may distinguish NMO from MS.
68
Imaging characteristics
Brain MRI and orbit MRI often reveal gadolinium enhance-
ment of the optic nerve during an acute attack of ON. A spinal 
cord MRI, when performed within days or weeks after an acu-
te myelitis attack, is very likely to show a central cord lesion 
that extends over three or more vertebral segments. Atrophy 
and central cavitation are seen in later stages of the disease. 
The manifestation of a longitudinally extensive lesion (on at 
least three vertebral segments) on spinal cord MRI is one of 
the most specific neuroimaging findings for NMO, with high 
sensitivity (98%) and specificity (83%).
6 However, MRI le-
sions are subject to timing issues; a lengthy T2-weighted le-
sion might not have developed fully in the first few days after 
clinical symptom onset, or it might have contracted or resolv-
ed over time.
6
Several studies have found asymptomatic and symptomatic 
brain lesions in NMO that were clearly distinct from the le-
sions in MS.
70-73 Lesions were observed on brain MRI in 60-
88% of patients during follow-up.
70,73-75 Asymptomatic lesions 
are more common, although symptomatic brain involvement 
is not rare in NMO. In our study analyzing brain MRIs of 78 
Korean NMOSD patients who were seropositive for AQP4-
Ab, 45% had symptomatic brain involvement. Brain lesions 
were identified on MRI at first presentation in 24 of 49 pa-
tients (49%), and most patients (83%) exhibited abnormali-
ties on brain MRI during the disease course.
73 The localization 
and configuration of the lesions were unique; the characteris-
tic brain lesions were 1) lesions involving corticospinal tracts 
such as the posterior limb of internal capsule and cerebral 
peduncle (44%), 2) extensive hemispheric lesions probably 
due to vasogenic edema (29%), 3) periependymal lesions sur-
rounding the aqueduct and the third and fourth ventricles 
(22%), 4) periependymal lesions surrounding the lateral ven-
tricles (40%), and 5) medullary lesions, often contiguous with 
cervical lesions (31%).
73 The brain lesions adjacent to the ven-
tricular system mirror the periventricular and hypothalamic 
localization of AQP4.
32 The extensive hemispheric lesions dif-
fered from those observed in regions of high AQP4 expression 
and were likely related to vasogenic edema; they sometimes 
looked like “spilled ink” and followed the white-matter tr-
acts.
73 This assumption was supported by diffusion-weighted 
images and apparent diffusion coefficient maps, which both ex-
hibited a high signal intensity without gadolinium enhance-
ment,
76 similar to the posterior reversible encephalopathy syn-
drome described previously.
77 Enhancement on brain MRI is 
not common and was seen in 13-36% of the cohort.
73-75 The 
most prominent type of enhancement was “cloud-like enhan-
cement,” which appears as multiple patches of enhancing le-
sions with blurred margins.
74
Laboratory findings
Several methods have been developed to test for NMO-IgG 
or AQP4-Ab; these include tissue-based IIFA
4 and cell-based 
IIFA,
40,78-80 radioimmunoprecipitation assays,
81 fluoroimmu-
noprecipitation assays,
45 ELISA,
82 flow cytometry,
83 and Wes-
tern blot analysis.
36 All showed good specificity (91-100%) for 
relapsing NMO, but the sensitivities varied widely (27-91%). New Insights into NMO
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In our experience using ELISA, AQP4-Ab levels and even se-
rostatus varied during follow-up. Therefore, negative test re-
sults cannot rule out the diagnosis of NMO or an NMOSD, 
and repeated testing is needed.
42
An analysis of the CSF during the acute phase may help to 
distinguish between NMO and MS. A previous study found 
pleocytosis [white blood cell count (WBC) >5 cells/mm
3] to 
be present in 11 of 15 monophasic patients (73%) and in 31 
of 38 relapsing patients (82%). WBCs higher than 50 cells/
mm
3 were observed in 5 of 14 patients (36%) in the mono-
phasic group and 13 of 38 patients in the relapsing group 
(34%).
14 Relapsing NMO is characterized by a rarity of oli-
goclonal IgG bands and the presence of a normal IgG index, 
whereas oligoclonal IgG bands are seen in 70-90% of MS 
patients in Western countries.
14,84,85
Diagnosis
Many NMOSD patients develop severe, irreversible impair-
ment early in the disease, making early diagnosis critical for 
effective long-term treatment to prevent attacks. In 1999, 
Wingerchuck et al.
14 proposed the first diagnostic criteria for 
NMO. The major criteria included three absolute require-
ments: ON, acute myelitis, and no symptoms implicating other 
CNS regions. To enhance the diagnostic specificity, at least 
one of three minor supportive criteria should be met: 1) brain 
MRI at disease onset appearing normal or not fulfilling MS 
imaging criteria, 2) spinal cord MRI showing a lesion ex-
tending over at least three vertebral segments, and 3) CSF 
with WBC ≥50 cells/mm
3 or ≥5 neutrophils/mm
3. Alterna-
tively, the presence of two of the three minor supportive crite-
ria plus bilateral ON, severe residual visual loss, or severe, fix-
ed, postattack weakness was sufficient.
86
After identifying NMO-IgG, revised diagnostic criteria for 
definite NMO were proposed. These included ON, myelitis, 
and at least two of the following three supporting criteria: 1) 
MRI evidence of a contiguous spinal cord lesion extending 
over at least vertebral segments, 2) brain MRI at onset non-
diagnostic for MS, and 3) NMO-IgG seropositivity (Table 1).
6 
CNS involvement beyond the optic nerves and spinal cord is 
compatible with NMO. This diagnostic combination was 99% 
sensitive and 90% specific for NMO.
6,86 An international task 
force recently recommended diagnostic criteria for NMO that 
included more detailed criteria for brain MRI results (Table 2).
87
After several reports describing NMO-IgG seropositivity 
in up to 60% of cases with LEM, necrotic myelopathy, and re-
current ON,
88,89 the spectrum of disorders classified as NMO 
was expanded and now includes the variants summarized in 
Table 3.
1
Table 1. Revised criteria for the diagnosis of NMO
6
Optic neuritis
Acute myelitis
At least two of the following three supportive criteria:
Contiguous spinal cord MRI lesion extending over at least 
  three vertebral segments
Onset brain MRI not meeting the diagnostic criteria for MS
NMO-IgG seropositivity status
NMO: neuromyelitis optica, MS: multiple sclerosis.
Table 2. Diagnostic criteria of NMO*
87
Major Criteria (all criteria are required, but may be separated by an unspecified interval)
1) Optic neuritis in one or more eyes
2)   Transverse myelitis, clinically complete or incomplete, but associated with radiological evidence of spinal cord lesion  
 extending over three or more spinal segments on T2-weighted MRI images and hypointensity on T1-weighted images when 
 obtained during acute episode of myelitis
3)   No evidence for sarcoidosis, vasculitis, clinically manifest systemic lupus erythematosus or Sjögren’s syndrome, or other 
 explanation for the syndrome.
Minor criteria (at least one must be fulfilled)
1.   Most recent brain MRI scan of the head must be normal or may show abnormalities not fulfilling Barkhof criteria used  
 for McDonald diagnostic criteria, including
†:
1) Non-specific brain T2 signal abnormalities not satisfying Barkhof criteria as outlined in McDonald criteria
2) Lesions in the dorsal medulla, either in contiguity or not in contiguity with a spinal cord lesion
3) Hypothalamic and/or brainstem lesions
4)   “Linear” periventricular/corpus callosum signal abnormality, but not ovoid, and not extending into the parenchyma 
 of the cerebral hemispheres in Dawson finger configuration
2. Positive test in serum or CSF for NMO-IgG/aquaporin-4 antibodies
*These criteria exclude limited or inaugural syndromes that may be NMO, such as recurrent transverse myelitis with longitudinally ex-
tensive spinal cord lesions, or recurrent ON; further study is warranted to clarify their relationship with NMO, especially in the setting of 
seropositivity for NMO-IgG/AQP4 antibodies, 
†Periodic surveillance with brain MRI scanning is necessary to monitor for the emergence 
of new lesions that may lead to a revised diagnosis.
NMO: neuromyelitis optica, CSF: cerebrospinal fluid. Kim W et al.
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Management
The optimal treatment for NMO has not yet been established, 
because no randomized controlled trials have been perform-
ed. Thus, treatment recommendations are based on small-siz-
ed case series, case reports, or even individual clinical obser-
vations.
Acute-phase treatment
High-dose	corticosteroids
For acute attacks, the traditional treatment is intravenous me-
thylprednisolone at 1,000 mg/day for 3-5 consecutive days. 
This recommendation is taken from studies of MS and idio-
pathic ON; no controlled therapeutic trials have investigated 
the effectiveness of steroids specifically in NMO.
90 Experience 
has indicated the need to continue steroids in the form of oral 
prednisone, with very slow tapering over months in the relaps-
ing form of the disease. Without tapering, patients tend to re-
lapse within weeks after an acute attack.
64 Wingerchuck et al.
14 
reported that 55 of 69 NMO patients with acute attacks show-
ed improvement after high-dose corticosteroid treatment. In 
cases with an unsatisfactory response, a repeated course of cor-
ticosteroids may be considered.
90
Therapeutic	plasmapheresis
A small proportion of patients fail to improve with high-dose 
corticosteroid therapy, and their prognosis can become grave.
91 
In such cases, therapeutic plasmapheresis should be consider-
ed. The removal of circulating autoantibodies, immune compl-
exes, cytokines, and other inflammatory mediators is thought 
to be the principal mechanism of action for plasmapheresis.
92 
Plasmapheresis treatments include conventional plasma ex-
change using centrifugation, double-filtration plasmapheresis, 
cryofiltration, and immunoadsorption.
93 Most previous studies 
have used conventional plasma exchange.
Favorable outcomes have been obtained following thera-
peutic plasma exchange for severe relapses of conventional 
MS and other devastating demyelinating disorders such as acu-
te myelitis, acute disseminated encephalomyelitis (ADEM), 
NMO, and recurrent myelitis.
94 However, there is a dearth of 
data for NMO, because most previous studies have included 
a broad spectrum of CNS demyelination patients with only a 
few cases of NMO.
95-100 In a retrospective study of 59 con-
secutive patients that included 22 MS, 10 NMO, and 10 AD-
EM patients, therapeutic plasma exchange was followed by 
moderate or marked functional improvement in 44.1% of the 
treated patients, which included 60% of the NMO patients.
95 
Seven of ten patients with severe isolated ON who were un-
responsive to high-dose corticosteroids showed improvement 
of visual acuity, although their NMO-IgG or AQP4-Ab levels 
were not measured.
96 In a study by Watanabe et al.
97 six NMO-
IgG-positive patients (three with ON and three with myelitis) 
who were unresponsive to high-dose intravenous methylpre-
dnisolone received plasma exchange (three to five exchanges, 
each comprising 2-3 L), and three (one with ON and two with 
myelitis) experienced a definite functional improvement. Cli-
nical improvement started to appear after one or two exch-
anges.
97 A retrospective study by Bonnan et al.
98 included 96 
severe spinal attacks in 43 Afro-Caribbean patients. As an add-
on therapy for 29 attacks, plasma exchange was given daily 
for 5 days, with the exchange of one volume of plasma with 5% 
albumin solution. The plasma-exchange-treated group showed 
improvements in neurological deficits.
Factors associated with moderate or marked improvement 
with plasma exchange were male gender, preserved reflexes, 
and early initiation of treatment.
95 In addition, early initiation 
of plasma exchange and improvement at discharge were sig-
nificantly associated with response at 6 months.
99 Minor ad-
verse events related to treatment in the course of plasma-ex-
change sessions were deep hypofibrinogenemia, hematoma 
at the puncture site, benign vagal reaction, asymptomatic bac-
teremia, abdominal syndrome, and extreme bradycardia.
98 Pa-
tients should be closely monitored for the usual risks associat-
ed with long-lasting immobility secondary to severe myelitis 
attacks, including thromboembolic events and respiratory/uri-
nary tract infections.
86
In guidelines established by the European Federation of 
Neurological Societies, early initiation of a rescue therapy with 
plasmapheresis is indicated in cases that are unresponsive to 
high-dose corticosteroids, with up to seven treatments every 
other day.
90 Therapeutic plasma exchange with seven exchan-
Table 3. NMO spectrum
1
NMO
Limited form of NMO
Idiopathic single or recurrent events of longitudinally extensive myelitis (≥3 vertebral segment spinal cord lesions seen on MRI)
Optic neuritis: recurrent or simultaneous bilateral
Asian optic-spinal multiple sclerosis
Optic neuritis or longitudinally extensive myelitis associated with systemic autoimmune disease
Optic neuritis or myelitis associated with brain lesions typical of NMO (hypothalamic, corpus callosal, periventricular, or brainstem)
NMO: neuromyelitis optica.New Insights into NMO
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ges of approximately 55 mL/kg each, administered every other 
day for 14 days, should be considered. However, larger-scale 
studies are needed to determine the optimal number of plasma 
exchanges.
A trial of double-filtration plasmapheresis for NMO-IgG-
positive patients was recently reported. In contrast to conven-
tional plasma exchange, which uses one plasma separator fil-
ter, double-filtration plasmapheresis uses two types of separa-
tor filter. The second filter selectively removes high-mole-
cular-weight proteins, including inflammatory cytokines.
101 
Eight patients were treated with double-filtration plasmaph-
eresis for a maximum of seven times per month for 3 months, 
and 3,000-4,000 mL of plasma were exchanged at each ses-
sion. Six of the eight patients (75%) showed therapeutic im-
provement after double-filtration plasmapheresis treatment, 
with improvements of vision (two patients), movement (seven 
patients), and sensory function (four patients). However, the cli-
nical status of the patients, especially whether they were in 
acute relapse, was not described.
Intravenous	immunoglobulin
Intravenous immunoglobulin (IVIg) has been used for the tr-
eatment of autoimmune disorders including autoimmune th-
rombocytopenia, chronic inflammatory demyelinating poly-
radiculoneuropathy, and Guillain-Barré syndrome.
102 The 
best-understood actions of IVIg include 1) modulation of 
pathogenic autoantibodies, 2) inhibition of complement acti-
vation and interception of membranolytic attack complex 
formation, 3) modulation of the inhibitory or activation Fc 
receptors on macrophages invading targeted tissues in nerve 
and muscle, 4) down-regulation of pathogenic cytokines and 
adhesion molecules, 5) suppression of T-cell functions, and 
6) interference with antigen recognition.
103 Considering the 
autoimmune mechanisms in the pathogenesis of NMO, IVIg 
could be a candidate treatment for NMO. However, IVIg has 
not yet been evaluated specifically for relapses of NMO and 
is rarely used for corticosteroid-refractory attacks.
104
Prevention of relapses
Many patients with NMO were initially diagnosed as having 
MS, and treated with approved immunomodulatory therapies 
such as IFN-β and glatiramer acetate. However, exacerbations 
of severe ON and myelitis have been reported with IFNβ-1b 
treatment in Japanese OSMS patients.
105,106 IFNβ-1a treatment 
was recently reported to have increased AQP4-Ab levels in a 
case of NMO.
107
Azathioprine
Azathioprine, a purine antimetabolite, interferes with the pro-
liferation of cells, and especially leukocytes,
108 and is com-
monly used as an immunosuppressive drug in the treatment 
of MS.
109 Azathioprine (2-3 mg/kg/day), usually in combina-
tion with oral prednisone (1 mg/kg/day), is widely employed 
as a preventative therapy.
86 In an observational case series, new-
ly diagnosed NMO patients received a maintenance combin-
ation treatment of prednisone (1 mg/kg/day) and azathioprine 
(2-3 mg/kg/day), with a gradual reduction of the prednisone 
dose after 2 months.
110 The patients remained stable, with no 
attacks, for at least 18 months, and their disability scores im-
proved significantly. Gastrointestinal complaints and leukope-
nia are the most frequently reported adverse effects of azathio-
prine therapy, and occur in more than 10% of patients. Infec-
tions, allergy, anemia, thrombocytopenia, and pancytopenia are 
also common. Most of these adverse effects are easily manag-
ed by dosage adjustment or therapy interruption; however, the 
risk for cancer increases with the treatment duration and cu-
mulative dose.
111
Low-dose	corticosteroids
The results of a retrospective study suggested that there was 
a beneficial effect of low-dose corticosteroid monotherapy in 
reducing the incidence of relapse in NMO. The annual re-
lapse rate was significantly lower during corticosteroid mo-
notherapy than during the period without corticosteroid ther-
apy. Relapses occurred significantly more often with corti-
costeroid doses of ≤10 mg/day than with doses of >10 mg/
day.
112 However, long-term treatment with corticosteroids of-
ten causes various complications.
Mycophenolate	mofetil
Mycophenolate mofetil (MMF) is a noncompetitive inhibitor 
of the enzyme inosine 5-monophosphate dehydrogenase. It 
controls lymphocyte proliferation and T-cell-dependent anti-
body responses by inhibiting purine synthesis.
113 The lym-
phocyte-selective inhibitory effect of MMF presents an ad-
vantage over azathioprine. In a case report of a 9-year-old 
girl who had a severe relapsing-remitting course of NMO de-
spite treatment with azathioprine and corticosteroid, a drama-
tic and sustained improvement occurred over a 2-year period 
of treatment with MMF.
114 In a retrospective case series with 
prospective telephone follow-up, 24 patients with NMOSD 
were treated with MMF (median dose, 2,000 mg/day). The 
median annualized relapse rate was lower after treatment than 
before treatment, and disabilities stabilized or decreased in 22 
of 24 patients (91%).
115 MMF is well tolerated in general, and 
its typical side effects involve the gastrointestinal (diarrhea, 
nausea, vomiting, and abdominal cramps), hematologic (leu-
kopenia, anemia, and thrombocytopenia), and genitourinary 
(urgency, frequency, dysuria, and sterile pyuria) systems. In 
contrast to azathioprine, MMF does not induce nephrotoxici- Kim W et al.
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ty, hepatotoxicity, or significant bone-marrow suppression.
116
Mitoxantrone
Mitoxantrone hydrochloride is an anthracenedione antineo-
plastic agent that has been approved as a treatment for sec-
ondary progressive and worsening relapsing-remitting MS. 
Mitoxantrone potentially suppresses Th lymphocytes and the 
humoral immune system via both macrophage and B-cell at-
tenuation.
117 It has been suggested that monthly intravenous 
infusion of mitoxantrone at 12 mg/m
2 for 6 months followed 
by three additional treatments every 3 months is effective for 
the prevention of NMO relapses. Among five patients enroll-
ed in a study of mitoxantrone treatment, two patients relaps-
ed once within the initial 5 months of treatment, and clinical 
improvement was seen on MRI in four patients.
118
In our experience with 20 frequently relapsing NMO pa-
tients, the median annualized relapse rate was reduced by 
75%, and 50% of patients became relapse-free during mitoxan-
trone treatment. Disability improved or stabilized in all pa-
tients. No patients had serious adverse effects during the mean 
follow-up period of 41 months after completing the therapy. 
Flow cytometric analysis of cell-surface markers revealed that 
mitoxantrone treatment preferentially affected CD27
+CD19
+ 
memory B cells.
119
Common adverse effects of mitoxantrone include leukope-
nia, amenorrhea, elevated liver enzyme levels, nausea, alope-
cia, bluish discoloration of the urine, and urinary tract infec-
tions. The most serious adverse consequences of mitoxan-
trone treatment, which occur infrequently, are cardiotoxicity, 
acute leukemia, and severe infection. The total dose of mito-
xantrone should be limited to a cumulative dose of 100 mg/m
2, 
since high doses have the potential to cause cardiotoxicity.
120 
One study found that therapy-related acute leukemia occurred 
in 0.3% of patients, and the median onset was at 18.5 months 
(range, 40-60 months) after the start of mitoxantrone treat-
ment; among the 25 patients for which outcomes were re-
ported, 6 died (24%). A relationship between total mitoxan-
trone dose and acute leukemia is suggested, given that more 
than 80% of the patients who developed acute leukemia had 
received >60 mg/m
2.
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Intravenous	immunoglobulin
There are two reports regarding IVIg for the preventive thera-
py of NMO. Two NMO patients with frequent attacks that 
were unresponsive to daily corticosteroids and azathioprine 
experienced no further attacks and showed improved neuro-
logical status after monthly IVIg infusion; 60 g in one patient 
and initially 0.4 g/kg/day for 5 days followed by 1.0 g/kg/
day over 2 consecutive days per month for the other patient.
122 
In the other report, a female NMO patient treated with month-
ly IVIg infusion (0.4 g/kg/day for 1 day) did not experience a 
relapse for more than 4 years, and her neurologic status also 
improved during follow-up.
123 Further studies assessing the ef-
fectiveness and safety of IVIg as a relapse-preventing therapy 
for NMO are needed.
Rituximab
Since NMO is related to humoral immunity, rituximab may be 
an effective treatment option. Rituximab is a chimeric, murine/ 
human monoclonal antibody directed against the CD20 anti-
gen expressed on pre-B cells and mature B cells. It causes de-
pletion of B cells when administered in vivo. The possibility 
of rituximab as a therapy for NMO was first suggested by 
the results of an open-label study in which eight consecutive 
patients received four intravenous infusions of rituximab at 
375 mg/m
2, administered once per week.
124 When the patients’ 
peripheral B-cell counts became detectable by fluorescence-
activated cell sorting, they were given the option of repeated 
rituximab treatment. Six of the eight patients became relapse 
free, and the median attack rate declined dramatically. Seven 
patients experienced substantial recovery of neurological 
function during the follow-up period, which averaged 1 year.
In a retrospective analysis of 25 patients with NMO who 
were treated with rituximab,
125 two rituximab regimens were 
used: 1) 375 mg/m
2 infused once per week for 4 weeks (n= 
18), and 2) 1,000 mg infused twice, with a 2-week interval be-
tween infusions (n=4). The median annualized pretreatment 
relapse rate was 1.7, and the rate dropped to 0 at a median fol-
low-up of 19 months. Disability improved or stabilized in 80% 
of the patients. Two patients died during the follow-up period, 
one from a brainstem relapse and one due to suspected septi-
cemia.
We recently completed a study of rituximab treatment in 
30 NMOSD patients.
126 The treatment protocol consisted of 
induction therapy (375 mg/m
2 once weekly for 4 weeks, or 
1,000 mg infused twice, with a 2-week interval between in-
fusions), followed by maintenance therapy. The maintenance 
therapy was a single dose of rituximab at 375 mg/m
2 admin-
istered whenever re-emerging CD27
+ memory B cells repre-
sented more than 0.05% of peripheral blood mononuclear 
cells. Of the 30 NMOSD patients, 29 showed a marked re-
duction in relapse rate after 24 months of rituximab treatment. 
The relapse rate was reduced significantly by 88%, and 70% 
of the patients became relapse-free over 24 months. Disability 
either improved or stabilized in 97% of the patients. AQP4-
Ab levels declined significantly following treatment with 
rituximab, consistent with the clinical response and the effect 
on CD27
+ memory B cells.
The side effects of rituximab include fever, chills, headache, 
asthenia, hypotension, bronchospasm, urticaria, and leukope-New Insights into NMO
124  J Clin Neurol 2011;7:115-127
nia.
127 It has also been associated with progressive multifocal 
leukoencephalopathy, which was reported in three patients tr-
eated for rheumatoid arthritis and two treated for SLE.
128 How-
ever, these patients had also received other immunosuppres-
sive agents prior to or in conjunction with rituximab. The long-
term side effects are uncertain.
Intermittent	plasma	exchange
The therapeutic efficacy of intermittent plasma exchange (dou-
ble-filtration plasmapheresis or conventional plasma exch-
ange) in combination with immunosuppressants to prevent re-
currence was evaluated in two NMO patients, and the recurr-
ence rate was significantly reduced after intermittent plasma 
exchange.
129
Conclusion
Recent advances in clinical, neuroimaging, laboratory, and pa-
thological hallmarks have established that NMO is a disease 
that is distinct from MS. Numerous clinical and experimental 
studies have implicated AQP4-Ab-mediated autoimmunity 
in the pathogenesis of NMO and provided a strong rationale 
for the use of therapies targeting humoral immunity in NMO. 
The development of the AQP4-Ab test has led to the recog-
nition of atypical presentations of NMO that are beyond the 
traditional view. These new insights into NMO enable us to 
make an early diagnosis of NMO and to apply appropriate 
immunotherapies in a wider spectrum of NMO patients.
A future avenue of investigation could include seronega-
tive NMO, genetic susceptibility factors, and the development 
of surrogate markers for clinical efficacy and of promising 
animal models of NMO. An improved understanding of NMO 
will lead to the identification of an optimal treatment strategy 
for this debilitating disease.
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